mjr111

Michael Root, MD, PhD

Contact Dr. Root

233 S. 10th Street
Room 802
Philadelphia, PA 19107

(215) 503-4564
(215) 923-2117 fax

Most Recent Peer-reviewed Publications

  1. Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity
  2. Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer
  3. Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus
  4. Evaluation of the efficiency of human immune system reconstitution in NSG mice and NSG mice containing a human HLA.A2 transgene using hematopoietic stem cells purified from different sources
  5. Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation
  6. Polyvalent side chain peptide-synthetic polymer conjugates as HIV-1 entry inhibitors
  7. Nucleoporin Nup50 stabilizes closed conformation of armadillo repeat 10 in importin α5
  8. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance
  9. Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding
  10. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil
  11. Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection
  12. Neutralization of Botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain
  13. Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins
  14. A human monoclonal antibody that binds serotype A botulinum neurotoxin
  15. C34, a membrane fusion inhibitor, blocks HIV infection of Langerhans cells and viral transmission to T cells
  16. Kinetic dependence to HIV-1 entry inhibition
  17. HIV-1 gp41 as a target for viral entry inhibition
  18. Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein
  19. Protein design of an HIV-1 entry inhibitor